JP7466748B1 - 肝機能の維持又は改善用組成物 - Google Patents
肝機能の維持又は改善用組成物 Download PDFInfo
- Publication number
- JP7466748B1 JP7466748B1 JP2023144316A JP2023144316A JP7466748B1 JP 7466748 B1 JP7466748 B1 JP 7466748B1 JP 2023144316 A JP2023144316 A JP 2023144316A JP 2023144316 A JP2023144316 A JP 2023144316A JP 7466748 B1 JP7466748 B1 JP 7466748B1
- Authority
- JP
- Japan
- Prior art keywords
- composition
- caryophyllene
- improving
- present
- liver function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 230000003908 liver function Effects 0.000 title abstract description 23
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 claims abstract description 84
- 235000019441 ethanol Nutrition 0.000 claims abstract description 57
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 claims abstract description 45
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 claims abstract description 42
- 206010019133 Hangover Diseases 0.000 claims abstract description 27
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 238000000034 method Methods 0.000 description 22
- 239000003826 tablet Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 12
- 230000035622 drinking Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 239000013589 supplement Substances 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000006199 nebulizer Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 244000223014 Syzygium aromaticum Species 0.000 description 6
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000008693 nausea Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- 229940034610 toothpaste Drugs 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 206010013082 Discomfort Diseases 0.000 description 4
- -1 alkali metal salts Chemical class 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007910 chewable tablet Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006191 orally-disintegrating tablet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NPNUFJAVOOONJE-IOMPXFEGSA-N (+)-beta-caryophyllene Chemical compound C1CC(/C)=C/CCC(=C)[C@@H]2CC(C)(C)[C@H]21 NPNUFJAVOOONJE-IOMPXFEGSA-N 0.000 description 2
- NPNUFJAVOOONJE-GFUGXAQUSA-N (-)-beta-caryophyllene Chemical compound C1CC(/C)=C/CCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-GFUGXAQUSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 2
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000025221 Humulus lupulus Species 0.000 description 2
- 235000008694 Humulus lupulus Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- HHZXYLJYXOHNNF-UHFFFAOYSA-N buddledin B Natural products CC1C=CCCC(=C)C2CC(C)(C)C2(O)C1=O HHZXYLJYXOHNNF-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- NPNUFJAVOOONJE-KBPBESRZSA-N (+)-beta-Caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@H]21 NPNUFJAVOOONJE-KBPBESRZSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000173371 Garcinia indica Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241001529742 Rosmarinus Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 229940124818 soft mist inhaler Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
β-カリオフィレンを有効量含有する、肝機能の維持又は改善用組成物。
飲酒後の不快感の軽減又は改善用である、[1]に記載の組成物。
二日酔い又は悪酔いの軽減又は改善用である、[1]に記載の組成物。
γ-GTP、AST、及び、ALTからなる群より選択される少なくとも1種の肝機能酵素値の改善用である、[1]に記載の組成物。
前記β-カリオフィレンの一日摂取量が、5~300mgである、[1]~[4]のいずれか1に記載の組成物。
飲酒前、飲酒後、又は、飲酒の翌日に摂取することを特徴とする、[1]~[4]のいずれか1に記載の組成物。
経口用、経肺用、又は、経鼻用、舌下用、又は、経皮用である、[1]~[4]のいずれか1に記載の組成物。
一つの実施形態において、本発明の肝機能の維持又は改善用組成物は、β-カリオフィレンを含有する。
β-カリオフィレンは、フトモモ科植物であるクローブ等から得られる精油に含有されている天然の揮発性成分であり、食品でも利用可能な香料として用いられている。
(1R,1β,4E,9α)-4,11,11-トリメチル-8-メチレン-ビシクロ[7.2.0]ウンデカ-4-エン
(+)-β-カリオフィレン:
(1S,4E,9R)-4,11,11-トリメチル-8-メチレンビシクロ[7.2.0]ウンデカ-4-エン
無機塩基としては、例えば、ナトリウムやカリウム等のアルカリ金属塩;カルシウムやマグネシウム等のアルカリ土類金属塩;アンモニウム塩やアルミニウム塩等が挙げられる。
有機塩基としては、例えば、エタノールアミンなどの第一級アミン;ジエチルアミン、ジエタノールアミン、ジシクロヘキシルアミン、N,N’-ジベンジルエチレンジアミンなどの第二級アミン;トリメチルアミン、トリエチルアミン、トリエタノールアミン、ピリジン、ピコリンなどの第三級アミン等が挙げられる。
塩基性アミノ酸としては、例えばリジン、アルギニンおよびオルニチン等が挙げられる。
本発明の組成物は、肝機能の維持又は改善に好適に用いられる。限定はされないが、肝機能の維持又は改善作用により、アルコールの代謝を促し、飲酒後の不快感の軽減又は改善効果を奏し得る。後述の実施例(試験例)において、本発明の組成物を、ヒトに摂取させた場合に、飲酒後の不快感の軽減又は改善効果が確認されている。
β-カリオフィレンをヒトに摂取させ、飲酒後の不快感に対して、どのような影響を生じるかを評価した。
β-カリオフィレン含有サンプルを、以下の通りに調製した。
純度80%のβ-カリオフィレン10mLとMCTオイル10mLとを精密に計量し、これらを混合した。その混合物をスポイト付きのガラス容器に移し、β-カリオフィレン含有サンプルとして用いた。
具体的な試験方法は以下の通りである。
被験者として、健常な成人12名を無作為に選出し、事前に各被験者で二日酔いを生じる飲酒量を確認した。別日において、各被験者に対して、飲酒前に上記β-カリオフィレン含有サンプルを、β-カリオフィレンの一日摂取量として約100mg摂取させ、各被験者で二日酔いを生じる飲酒量を飲酒し、翌朝にアンケートを実施した。β-カリオフィレン含有サンプルの摂取は、舌下により行っている。当該摂取方法では、舌下により吸収される他、唾液と共に経口摂取され、β-カリオフィレンが揮発性成分であるため、経鼻摂取や経肺摂取も同時に行い得る。
<評価基準>
1点:全く効果を感じなかった
2点:あまり効果を感じなかった
3点:わからない
4点:効果を感じた
5点:とても効果を感じた
結果を図1に示す。
実感した効果は、以下の7項目であり、該当する効果にチェックをすることにより回答した。
・胃もたれが軽減した
・胃もたれが軽減した
・頭痛が軽減した
・吐き気がなくなった
・激しい動機が落ち着いた
・疲労感・脱力感が減った
・その他(自由回答)
Claims (4)
- β-カリオフィレンを有効量含有する、飲酒後の不快感、二日酔い又は悪酔いの軽減又は改善用組成物。
- 前記β-カリオフィレンの一日摂取量が、5~300mgである、請求項1に記載の組成物。
- 飲酒前、飲酒後、又は、飲酒の翌日に摂取することを特徴とする、請求項1に記載の組成物。
- 経口用、経肺用、又は、経鼻用、舌下用、又は、経皮用である、請求項1に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023144316A JP7466748B1 (ja) | 2023-08-18 | 2023-09-06 | 肝機能の維持又は改善用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023133382 | 2023-08-18 | ||
JP2023144316A JP7466748B1 (ja) | 2023-08-18 | 2023-09-06 | 肝機能の維持又は改善用組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023133382 Division | 2023-08-18 | 2023-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP7466748B1 true JP7466748B1 (ja) | 2024-04-12 |
Family
ID=90623413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023144316A Active JP7466748B1 (ja) | 2023-08-18 | 2023-09-06 | 肝機能の維持又は改善用組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7466748B1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184036A2 (ru) | 2012-06-07 | 2013-12-12 | Getman Mikhail Alexandrovich | Гепатопротекторное средство |
WO2022261264A1 (en) | 2021-06-08 | 2022-12-15 | Resonate Blends Llc | Methods and cannabis compositions for achieving a reliable, targeted and specific consumer experience |
-
2023
- 2023-09-06 JP JP2023144316A patent/JP7466748B1/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013184036A2 (ru) | 2012-06-07 | 2013-12-12 | Getman Mikhail Alexandrovich | Гепатопротекторное средство |
WO2022261264A1 (en) | 2021-06-08 | 2022-12-15 | Resonate Blends Llc | Methods and cannabis compositions for achieving a reliable, targeted and specific consumer experience |
Non-Patent Citations (1)
Title |
---|
Zoltan V. VARGA et al.,"β‐Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice",British Journal of Pharmacology,2017年02月22日,Vol. 175, No. 2,p.320-334,DOI: 10.1111/bph.13722 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6271472B2 (ja) | グリシンを含有する熟眠障害改善剤 | |
WO2005097101A1 (ja) | 睡眠改善用組成物 | |
CN103168907B (zh) | 清凉增强组合物 | |
CA3057172A1 (en) | Rapid and controlled delivery of compositions with restored entourage effects | |
US8636985B2 (en) | Functional formulation in chewing gum | |
WO2013051728A1 (ja) | 睡眠の質改善剤 | |
CN110167549A (zh) | 快速作用的基于植物的药用化合物和营养补充剂 | |
WO2012165406A1 (ja) | 精神高揚剤および精神高揚用組成物 | |
JP6100692B2 (ja) | 睡眠の質改善剤 | |
JP2002097136A (ja) | 喫煙欲求抑制組成物 | |
JP2007204408A (ja) | 線毛運動活性化剤及びそれを含む飲食品 | |
US20070014834A1 (en) | Apparatus and methods of improved delivery of orally-administered therapeutic substances | |
JP7466748B1 (ja) | 肝機能の維持又は改善用組成物 | |
JP2008094743A (ja) | 摂食・嚥下改善食品 | |
US20060094734A1 (en) | Composition and method for inducing alertness | |
JP2005281272A (ja) | 末梢血流改善剤 | |
US9198943B2 (en) | Silene capensis for inhibiting cravings | |
JP5691638B2 (ja) | プロポリス組成物およびその製造方法 | |
JP2006333872A (ja) | グリシンを含有する食品及びその用途 | |
JP2022547409A (ja) | 充填顆粒、これらの製造方法及びこれらの使用 | |
JP3656972B2 (ja) | アルコール臭低減剤 | |
JP5998351B2 (ja) | いびきの防止または改善用組成物 | |
US9844228B2 (en) | Spray method and composition for reducing psychological hunger | |
FR3057777A1 (fr) | Composition a visee expectorante et decongestionnante des voies respiratoires, son procede de preparation et son utilisation | |
JP2012131823A (ja) | 線毛運動活性化剤及びそれを含む飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230906 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230906 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20230912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230912 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240116 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240321 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240402 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7466748 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |